Close

Prof Pontiano Kaleebu

Professor of Immunovirology*

United Kingdom

Affiliations

MRC/UVRI and LSHTM Uganda Research Unit

Selected Publications

High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer, AJ; Dilthey, AT; Pollard, M; Gurdasani, D; Karakoc, E; Carstensen, T; Muhwezi, A; Cutland, C; Diarra, A; Da Silva Antunes, R; Paul, S; Smits, G; Wareing, S; Kim, H; Pomilla, C; Chong, AY; Brandt, DY C; Nielsen, R; Neaves, S; Timpson, N; Crinklaw, A; Lindestam Arlehamn, CS; Rautanen, A; Kizito, D; Parks, T; ... Sandhu, MS.
2024
Nature medicine
Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda.
Anywaine, Z; HANSEN, C; Warimwe, GM; Abu-Baker Mustapher, G; Nyakarahuka, L; Balinandi, S; Ario, AR; Lutwama, JJ; ELLIOTT, A; KALEEBU, P;
2024
Virology journal
Viruses associated with measles-like illnesses in Uganda.
Namuwulya, P; Ashraf, S; Niebel, M; Ssekagiri, A; Tushabe, P; Kakooza, P; Tong, L; Bukenya, H; Jerome, H; Davis, C; Birungi, M; Turyahabwe, I; Mugaga, A; Eliku, JP; Francis, A; Nakabazzi, L; Nsubuga, F; Katushabe, E; Kisakye, A; Ampeire, I; Nanteza, A; KALEEBU, P; Bakamutumaho, B; Nsamba, P; Kazibwe, A; ... THOMSON, EC.
2024
The Journal of infection
Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
Kimbugwe, G; Vatrinet, R; Mwanga, JA; Kakuru, R; Mpeirwe, D; Logoose, S; Opio, K; Kambale, M; SEELEY, J; Grais, RF; Marquer, C; KALEEBU, P; SSALI, A;
2024
Vaccine
HLA-A*23 Is Associated With Lower Odds of Acute Retroviral Syndrome in Human Immunodeficiency Virus Type 1 Infection: A Multicenter Sub-Saharan African Study.
Lindquist, L; Kilembe, W; Karita, E; Price, MA; Kamali, A; KALEEBU, P; Tang, J; Allen, S; Hunter, E; Gilmour, J; Rowland-Jones, SL; Sanders, EJ; Hassan, AS; Esbjörnsson, J;
2024
Open forum infectious diseases
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.
Ankunda, V; Katende, JS; Oluka, GK; Sembera, J; Baine, C; Odoch, G; Ejou, P; Kato, L; COVID-19 Immunoprofiling Team,; KALEEBU, P; Serwanga, J;
2024
Frontiers in immunology
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.
Serwanga, J; Ankunda, V; Katende, JS; Baine, C; Oluka, GK; Odoch, G; Nantambi, H; Mugaba, S; Namuyanja, A; Ssali, I; Ejou, P; Kato, L; COVID-19 Immunoprofiling Team,; Musenero, M; KALEEBU, P;
2024
Frontiers in immunology
Re-testing as a method of implementing external quality assessment program for COVID-19 real time PCR testing in Uganda.
Okek, EJ; Masembe, FJ; Kiconco, J; Kayiwa, J; Amwine, E; Obote, D; Alele, S; Nahabwe, C; Were, J; Bagaya, B; Balinandi, S; Lutwama, J; KALEEBU, P;
2024
PloS one
HIVseqDB: a portable resource for NGS and sample metadata integration for HIV-1 drug resistance analysis.
Ssekagiri, A; Jjingo, D; BBOSA, N; Bugembe, DL; Kateete, DP; Jordan, IK; KALEEBU, P; SSEMWANGA, D;
2024
Bioinformatics advances
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
WAJJA, A; Nassanga, B; Natukunda, A; Serubanja, J; Tumusiime, J; Akurut, H; Oduru, G; Nassuuna, J; Kabagenyi, J; Morrison, H; Scott, H; Powell Doherty, R; Marshall, JL; Cabrera Puig, I; COSE, S; KALEEBU, P; WEBB, EL; Satti, I; McShane, H; ELLIOTT, AM; TB042 Study Team,;
2024
The Lancet. Infectious diseases
See more information